Individualized Antithrombotic Therapy for Patients With Ischemic Cerebrovascular Disease

• Status: Unknown status
• Trial end date: 2018-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To investigate the therapeutic effect of individualized treatment of antiplatelet in secondary prevention of ischemic stroke.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Xuanwu Hospital, Beijing
• Collaborators: Chinese PLA General Hospital; Peking University People's Hospital

Criteria

Inclusion Criteria:

• 14 years of age or older

• no gender aspirin or clopidogrel for ischemic cerebrovascular disease Primary or secondary prevention of ischemic stroke patients

• The researcher (or principal) signs the informed consent form

Exclusion Criteria:

• Significant head trauma or stroke in the last 3 months

• 3 months to accept intracranial, spinal surgery or other parts of large surgery

• In the last week there is an incurable part of the artery puncture

• Acute bleeding constitution, including platelet count <100 × 109 / L or other conditions

• within the last 48h heparin treatment, APTT higher than the upper limit of normal range

• Oral anticoagulant: INR> 1.7 or PT> 15s

• The presence of intracranial tumors, aneurysms or arteriovenous malformations

• Patients with any of the following cardioembolic-related illnesses are identified:

rheumatic mitral or aortic stenosis, prosthetic heart valves, atrial fibrillation, atrial flutter, sick sinus syndrome, left atrial myxoma, Open foramen ovale, left ventricular mural thrombus or valvular vegetation, congestive heart failure, bacterial endocarditis, or any other cardiovascular disease not suitable for enrollment; (as determined by the investigator)

• Severe liver and kidney dysfunction

• Life expectancy is less than 1 year

• Pregnant or lactating women

• Participating in other clinical studies, or have participated in other clinical studies within the 3 months before enrolling, or have already participated in this research

• Allergic or intolerant to aspirin or clopidogrel

• There are stomach lesions, such as gastritis, gastric ulcer and so on

• Do not want to follow-up or poor treatment compliance